ArticleBMC women's health2025
Advanced ovarian cancer with malignant bowel obstruction treated with multidisciplinary therapy resulting in long progression-free survival: a case report.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAdvanced ovarian cancer complicated by malignant bowel obstruction is generally considered a terminal event, especially when deemed inoperable, with an expected survival of only a few weeks. We report the case of a patient who was initially judged inoperable but who survived approximately 40 months without disease progression thanks to an active multidisciplinary approach. CASE PRESENTATION: A 76-year-old woman presented with bowel obstruction, massive ascites, and an Eastern Cooperative Oncology Group performance status of 4. Ultrasound-guided peritoneal biopsy confirmed a high-grade serous carcinoma of gynecological origin. After a multidisciplinary team discussion, the patient was deemed unsuited to surgical management. Despite this, she received total parenteral nutritional support and symptomatic control, followed by three cycles of neoadjuvant carboplatin-paclitaxel. This treatment led to a substantial reduction in her disease burden and an improvement in her performance status, permitting interval debulking surgery. The outcome of surgery was optimal cytoreduction (residual disease < 1 cm). Six additional cycles of adjuvant chemotherapy were administered (carboplatin was replaced with nedaplatin after the development of hypersensitivity). Germline breast cancer susceptibility gene 2 mutation was identified, and maintenance olaparib was initiated (300 mg twice daily, later reduced). For approximately 40 months, imaging showed good tumor control with no signs of progression, and serum cancer antigen 125 levels remained within normal limits. The patient ultimately succumbed to therapy-related myeloid neoplasms complicated by bleeding and infection, without evidence of ovarian cancer progression.
conclusionsPatients with advanced ovarian cancer who are initially diagnosed with an inoperable malignant bowel obstruction may still derive a substantial survival benefit from an integrated multidisciplinary treatment regimen. The findings of this study challenge the current negative prognosis of such patients and highlight the need for prospective studies to further explore the potential benefits of this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.